Synergy Pharmaceuticals Stock Company Profile

Description

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. The company has a research collaboration with BIND Therapeutics, Inc. to develop ACCURINS for treatment of a range of cells with novel therapeutic payloads. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.